688062.SH
迈威生物-U
SSE · Healthcare · Biotechnology · CN
CNY 29.23
−6.22%Year over year
Reported trailing growth
- Revenue
- +321.1%
- EBITDA
- —
- EBIT
- +20.0%
- EPS
- +18.3%
- Free cash flow
- +57.2%
- Operating cash flow
- +63.5%
Forward estimates
Based on analyst estimates
- Revenue
- -76.9%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +188.0%
- EBITDA
- +17.4%
- EBIT
- +8.4%
- Net income
- +7.1%
- EPS
- +6.9%
- Free cash flow
- +65.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026